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12.1
Outcome after comprehensive neck dissection with positive surgical
margins
L.E. Smeele, C.R. Leemans, R. Tiwari, 1. van derWaal, G.B. Snow, Dept. Oral and
Maxillofacial Surgery, Dept. ORL, University ofAmsterdam,The Netherlands
Introduction: A positive surgical margin in a neck dissection
specimen is a poor prognostic factor. Neck-recurrence rates may
be improved with postoperative radiotherapy.
Methods: Out of a series of 1165 patients who underwent
comprehensive neck dissections for squamous cell carcinoma of
the lip/oral cavity, oropharynx, hypopharynx, or larynx between
1974-1995, 72 patients (6.1%) had positive margins at
histopathological examination. During surgery, fixation of
metastases to non-lymphatic structures was noted in 55
dissections. Adjuvant treatment consisted of radiotherapy with
curative intent in 33, palliative radiotherapy in 13, and
chemotherapy in 14 patients. Cumulative survival distributions
were estimated by the Kaplan-Meier analysis and differences
between groups were analysed with the Logrank test.
Results: Recurrence in the ipsilateral neck was 62.6% at five years
and the median time to recurrence was 20 months. After treatment
with radiotherapy with curative intent this was 44.2%. The
remaining necks recurred in 84.2%. The difference between the
two groups is statisticallyhighly significant (p<0.00001).
Conclusion: Regional recurrence free rates after neck dissection
with tumour at the margins are extremely poor, but can be
improved considerably by a curative dose of radiotherapy
postoperatively ifthis modality is still available.
12.3
Neck lymph node biopsy did not increase the distant metastases in AJCC Tl- 3N,Jnasopharyngeal carcinoma patients
P.C. Pail, N.M. Tsang', C.F. Lin2, C.K. Tseng', S. Tang', 'Dept. ofRad. Oncology,
2Dept. ofPublic Health, Chang Gung College ofMedicine and Technology, Linkou,
Taiwan
Purpose: To investigate whether the neck lymph node biopsy
procedure increases the distant metastases rate in AJCC T1_3NI-3
nasopharyngeal carcinoma (NPC) patients. Material and
Methods: From February 1979 to December 1991, 1181 NPC
patients were treated in Chang Gung Memorial Hospital radiation
oncology department. These patients completed the proposed
course ofnasopharyngeal treatment equal or greater than 64 Gy
and were followed up for more than 5 years. Five hundred and
forty-three patients belonged to AJCC TI-3NI-3 stage and in which
88 cases had neck lymph node operation procedure (aspiration 7,
incision 39, excision 40, and dissection 2). Results: No statistical
difference is recognized in age, operation method, or the time
interval between operation and start oflocal treatment but sex, N
stage, and neck area electron boost. Discussion: In this study,
though it is suggested that neck lymph node operation before
local-regional irradiation do not increases the distant metastatic
rate in AJCC TI-3NI.3 NPC patients.
12.2
Is planned neck dissectionindicated ifchemotherapy is added to 60Gy?
G. Sanguineti', R. Corvo', M. Benasso2, A. Bacigalupo', G. Margarino3, V.
Vitale', Depts. of 'Radiation Oncology, 2Medical Oncology Ist, 3Surgical
Oncology, National Institute for Cancer Research, Genoa, Italy
Introduction: Planned neck dissection (PND) for large volume
N2-3 neck disease is recommended after moderate dose
radiotherapy (RT). The purpose ofthe present study is to assess if
routine neck dissection is necessary even after chemotherapy
alternated with 60 Gy.
Methods: From 1987 to 1995, 53 NI-3 heminecks from 43
patients with HN-SCC have been treated with alternated
chemoradiotherapy (60 Gy at 2 Gy/fraction alternated with 4
cycles ofcisplatin and 5-fluorouracil) at the National Institute for
Cancer Research ofGenoa. Forlivingpatients, median follow up is
37 months(range: 24-67.9 months).
Results: After chemoradiotherapy alone, 2-yr neck control
probabilities (NCP) are 86+8%, 59+10% and 0 for NI, N2a-b and
N3 neck stages, respectively (p=0.005). Two-year NCP for 33
complete responses is 85+8%, while, at the same time interval it is
15+8% for 20 partial responses (p<0.0001). A further breakdown
ofNCP by neck stage and response shows no difference between
NI and N2a-b lesions in both partial (p=0.48) and complete
responses (p=0.54). Five (9%) heminecks have developed severe
(RTOGgrade >2) subcutaneous late reactions.
Conclusions: PND is recommended even after moderate dose RT
alternated with chemotherapy unless response is accounted for
patients' selection.
12.4
Organ preservation in pharyngeal carcinoma presenting with advanced
cervical metastasis
AS. Allal', P. Dulguerov2, S. Bieri', W. Lehmann2, J.M. Kurtz', 'Dept. of
Radiation Oncology, 2Dept. ofHead and Neck Surgery, University ofGeneva,
Switzerland
Objective: To evaluate treatment results in T1-T3 pharyngeal cancers
presenting with extensive neck disease (N2-N3), using neck dissection
followed by radical locoregional radiotherapy (RT). To compare these
results with those obtained in comparable patients treated by radical RT
alone.
Patients and Intervention: 41 patients with carcinomas of the oro- or
hypopharynx, staged as T1-3 N2-3 MO (AJCC stage IV), were treated
with radical RT,,using a progressively accelerated concomitant boost
schedule. RT was the sole treatment in 17 patients (group 2) and
followed surgical neck dissection in 24 (group 1).
Outcome: Three-year locoregional control and overall survival. Post-
operative complications, acute and late radiation effects.
Results: Actuarial locoregional control was 73% and 55% for groups 1
and 2, respectively (p= 0.52). After salvage surgery regional control was
78% and 69 % in groups I and 2, respectively (p=0.8), and the
corresponding 3-year actuarial overall survival rates were 37% and 50%.
(p= 0.42). Severe postoperative complications were observed after neck
dissection in 4 patients (16%). Acute toxicity during RT was similar in
the two groups. Late toxicities were also similar, except for two patients
in group 1 who developed severe laryngeal edema.
Conclusion: This atypical approach, consisting of neck dissection
followed by radical RT to the primary tumor and neck, represents a valid
treatment option in this subset of patients, allowing good control of
advanced neck disease, while at the same time conserving
pharyngolaryngeal function.38 Radiochemotherapy
12.5
Monitoring of 5-FU pharmacokinetics in cervical lymph node metastases from
headand neck carcinomasby means of in vivo 19F MR spectroscopy
H.P. Schlemmer', A. Dietz2, M. Becker', P. Wollensack2, P. Bachert', V. Rudat3, B.
Vanselow2, M. Knoppl, M. Wannenmacher3, H. Weidauer2, G. van Kaick', 'German
Cancer Research Center, 2'3University ofHeidelberg, Germany
Introduction: In patients with squamous cell carcinomas (SCC) of
the. head and neck response rates may be improved by using
combined radio/chemotherapy with 5-fluorouracil (5-FU). Purpose
of this study is to evaluate the potential of in vivo '9F magnetic
resonance spectroscopy ('9F MRS) for monitoring individual
pharmacokinetics of5-FU.
Subjects and Methods: Patients with advanced SCC ofthe oro-
and hypopharynx (T3/T4; N2b,c/N3) were examined. All patients
underwent an accelerated hyperfractionated concomitant-boost
radio/chemotherapy. 5-FU (600 mg/[m2*d]) and carboplatin (70
mg/[m2*d]) were applied during week 1 and 5 of treatment. '9F
MRS was performed with a 5 cm surface coil at 1.5 T on day 1 of
the 1' and 2nd cycle of chemotherapy. '9F MR spectra were
acquired during the 50 min infusion of5-FU.
Results: In this ongoing study in 8/9 patients resonances of 5-FU,
a-fluoro-b-alanine (FBAL) and 5-fluoro-5,6-dihydrouracil (DHFU)
were detected. During the 2nd cycle of chemotherapy enhanced
levels ofintratumoral 5-FU were observed in 7/8 patients.
Discussion: Individual 5-FU pharmacokinetics can be monitored
noninvasively using '9F MRS. The observed enhancement of 5-FU
levels during the radio/chemotherapy indicate a modulation of 5-
FU pharmacokinetics by irradiation.
12.7
Oxygen distribution in lymph node metastases, primary tumors and
normal tissues in head and neck carcinomas
M. Bloching', A. Becker2, J. Dunst2, A. Berghaus', 'Dept. of ORL, 2Dept. of
Radio-Oncoclogy, University ofHalle/Saale, Germany
Background: There is a correlation between the effect ofradiation
and the p02-tension in malignant tissues. In this study we
determined the oxygen distribution in Impyh node metastases (LN),
primary tumors (PT) and the stemocleidomastoid muscle (SM) in
patients with carcinomas of the head and neck region. We
measured thep02-pressure at 19 patients with the Eppendorf pO2-
Histograph.
Results: The median P02 ofprimarytumors, neck node metastases
as well as the sternocleidomastoid muscle showed a broad
vanance. The medianp02-values in malignant tissues were in 14 of
15 cases below the value ofSM. 80% ofPT and more than 90% of
LN showed a p02-pressure below 5 mm Hg. There was a strong
correlation ofthe determined oxygenation ofPT and LN.
Conclusions: The preliminary data of this cooperation-study
showed a comparable oxygenation of advanced PT and their
regional lymph node metastases in squamous cell carcinomas of
head and neck region. This results may improve the knowledge
about the relationsship of tumor oxygenation and malignant
progression under radiation therapy.
12.6
Rise of oxygenation in cervical lymph node metastasis of advanced cancer of
the head and neck during the initial course of radiochemotherapy
A. Dietz', V. Rudat2, B. Vanselow', C. Conradt3, M.J. Eble2; H. Weidauerl, 'Dept. of
RL, 2Dept. of Rad. Oncology, 3Inst. of Med. Biometry, University of Heidelberg,
Germany
Introduction: The therapeutic effect ofradiotherapy depends to a
significant extent on the degree of oxygenation oftumor tissue. It
has been hypothesised that during radiation treatment, a
reoxygenation of hypoxic tumor tissue takes place. To test this
hypothesis, we have investigated wether reoxygenation in lymph
node metastases could be determined by invasive partial oxygen
pressure measurements.
Patients and Methods: Via a hyperdermic needle inserted
transcutaneously into tumor positive lymph nodes, polarographic
oxygen determinations (EppendorfpO2-histograph) were made on
18 patients with advanced squamous cell carcinomas of the oro-
and hypopharyx. These measurements were performed before
therapy and a week after onset of accelerated radio- or
radiochemotherapy.
Results: Low PO2 values before treatment (median 18.9 mmHg,
average 18.6 mmHg) and a hypoxic fraction (pO2< 5 mmHg) of
40.3% (median) indicated manifest tumor hypoxia. After one week
oftreatment a significant increase in the median (25.5 mmHg) and
the average PO2 (24.1 mmHg) as well as a reduction in the hypoxic
fraction (mean value of median shift: 13.4% PO2 < 5 mmHg, p <
0.03) were observed.
Conclusion: Thus, invasive PO2 histography fulfils the
requirements for a method to confirm tumor hypoxia in head and
neck tumors. The results obtained indicate that reoxygenation
occurs during the initial phases ofradio- and radiochemotherapy.
12.8
Taxotere" (Docetaxel) in the treatment of patients with locally
advanced and metastatic head & neck cancer
P. Schoffski, T. Weihkopf, A. Ganser, Dept. of Hematology/Oncology,
Hamnover University Medical School, Germany
Background: Taxoterec (Docetaxel) is a new cytotoxic agent obtained
through a semisynthetic process from the needles of the European yew tree,
Taxus Baccata. Taxotere° interferes with the rate and extent of microtubule
assembly and disassembly as one major component of the cell proliferation
process. The drug has been discovered in 1986, tested in clinical trials since
1990 and approved in 55 countries for treatment of solid tumors since 1995.
Taxotere° is clinically active in a broad range of malignancies. Safety and
Toxicity: Short-lasting neutropenia rarely complicated by fever or infections is
the main dose limiting toxicity of the drug. Acute hypersensitivity reactions
and fluid retentios have been observed in early clinical trials, but are now
markedly reduced by the use of corticosteroid co-medication. In contrast to
other taxoids, Taxotere° has no clinically relevant cardiotoxicity. Single-agent
activity: Taxotere° is commonly given at a dose of 100 mg/M2 BSA as a one
hour i.v. infusion every three weeks. The antitumor activity of single-agent
Taxotere° in patients with head and neck cancer has been evaluated in a
number of European, North American and Japanese trials, resulting in
objective response rates of 23-42% in patients with metastatic disease or
locoregional recurrences (Catimel et al. 1994, Fuji et al. 1995, Posner et al.
1996, Couteau et al. 1996, Ebihara et al. 1997). Combination chemotherapy:
The combination of Taxotere° with other active antitumor agents appeared
both feasible and clinically active in Phase I. Various regimens have been
evaluated in recent Phase II trials in patients with advanced and/or metastatic
head and neck cancer (Schoffski et al. 1996, Janinis et al. 1997, Posner et al.
1997). Objective responses of 55-100% have been reported in patients with
locally advanced, recurrent or metastatic disease, including 25-67% complete
remissions. Future directions: The good antitumor activity of Taxotere°
combinations has led to the design ofa number ofrandomized Phase III trials,
which are currently initiated by cooperative study groups both in Europe and
the U.S. These comparative studies will further define the role of this
promising newagent for treatment ofpatients with head and neck cancer.Radiochemotherapy 39
12.9
Prospective study of accelerated radiochemotherapy in patients with advanced
head and neck cancer: Prognostic factors for distant metastases
V. Rudat', A. Dieti2, J. Nollelt2, C. Conradt3, H. Weidauer2, M. Wannenmacherl,
'Dept. of Radiation Oncology, 2Dept. of Otolaryngology, Head and Neck Surgery,
3Inst. ofMedical Biometry. University ofHeidelberg, Germany
Introduction: To identify prognostic factors for treatment
outcome in a prospective study.
Patients and Methods: 68 patients with advanced head and neck
cancer without distant metastases were treated with an accelerated
radiochemotherapy with Carboplatin in a prospective study. 63
patients (93%) had stage IV disease. At the time ofthe analyses,
the median follow up time was 637 days and the median actuarial
survival time 570 days. Twenty-eight (41%) patients developed
distant metastases. In 56 patients, the total tumor volume was
quantitatively measured using pretreatment diagnostic CT-scans
and in 51 patients serum LDH values were determined before
therapy.
Results: Univariate analysis revealed the total tumor volume (p =
0.04) and LDH values (p = 0.02) as significant prognostic factors
on the metastases free survival time (logrank test). This could be
confirmed by a multivariate Cox regression analysis (n = 40).
Conclusion: CT-derived tumor volume parameters may prove
useful in future research studies to better understand tumor
biology. The predictive value ofLDH hasbeen recognized in other
tumor entities.